RICERCA
AUTORI
RIVISTE
Sfoglia per AUTORE
ORTEGA C
Collezione ASL Cuneo 2
Items : 38
[What patients with cancer think about the dehospitalization. A survey of Cipomo.]. in Recenti progressi in medicina / Recenti Prog Med. 2024 May;115(5):232-237. doi: 10.1701/4262.42402.
2024
ASL Cuneo 2
Barni S; Aschele C; Blasi L; Giordano M; Ortega C; Pinotti G; Artioli F; Fioretto L; Daniele B; Aprile G; Silva RR; Montesarchio V;
Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group? in European urology oncology / Eur Urol Oncol. 2024 Feb;7(1):102-111. doi: 10.1016/j.euo.2023.07.003. Epub 2023 Jul 21.
2024
ASL Cuneo 2
AOU Novara
Porta C; Battelli N; Bracarda S; Sorgentoni G; Monteiro FSM; Mollica V; Rizzo A; Zabalza IO; Bimbatti D; Soares A; Bisonni R; Rebuzzi SE; Roviello G; Incorvaia L; Morelli F; Santini D; Vau N; Bhuva D; Küronya Z; Mosca A; Landmesser J; Milella M; Messina C; Bassanelli M; Ortega C; Grillone F; Procopio G; Sunela K; Caffo O; et alii...
Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2024 Apr 18;73(6):106. doi: 10.1007/s00262-024-03682-w.
2024
ASL Cuneo 2
Mosca A; Morelli F; Bisonni R; Bamias A; Santini D; Herchhorn D; Kanesvaran R; Inman E; Caitano M; Messina C; Martignetti A; Kopecky J; Milella M; Procopio G; Abahssain H; Roviello G; Kopp RM; Bassanelli M; Fernandez M; Cutuli HJ; Grillone F; Aceituno LG; Seront E; de Carvalho Fernandes R; Nogueira L; Mennitto A; Dauster B; Monteiro FSM; Barillas A; et alii...
TEAM Study: Upfront Docetaxel Treatment in Patients With Metastatic Hormone-Sensitive Prostate Cancer: A Real-World, Multicenter, Retrospective Analysis. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2024 Apr;22(2):56-67.e16. doi: 10.1016/j.clgc.2023.08.006. Epub 2023 Sep 7.
2024
ASL Città di Torino
AO Cuneo
ASL Asti
ASL Cuneo 2
AOU Città della Salute di Torino
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Filippi R; Brusa F; Prati V; Vana F; Mennitto A; Maio MD; Buttigliero C; Vignani F; Dionisio R; Icardi M; Guglielmini P; Buosi R; Stevani I; Vormola R; Numico G; Depetris I; Comandone A; Gennari A; Airoldi M; Rossi M; Vellani G; Ortega C; Ruatta F; Tucci M; Pisano C; Turco F; Arnaudo E; Fea E; Vanella P; et alii...
2024
ASL Cuneo 2
ASL Asti
Giannatempo P; Polymeropoulos A; Stellato M; Ambrosini P; Gusmaroli E; Cavalli C; Guadalupi V; Claps M; Raggi D; Rametta A; Ortega C; Tucci M; Buti S; Pipitone S; Iacovelli R; Calareso G; Alessi A; Procopio G; Miceli R; Necchi A;
2024
ASL Cuneo 2
ASL Asti
Stellato M; Giannatempo P; Polymeropoulos A; Guadalupi V; Claps M; Ambrosini P; Raggi D; Rametta A; Cavalli C; Gusmaroli E; Ortega C; Tucci M; Buti S; Pipitone S; Iacovelli R; Calareso G; Alessi A; Procopio G; Miceli R; Necchi A;
Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study. in Cancer immunology, immunotherapy : CII / Cancer Immunol Immunother. 2023 Nov;72(11):3665-3682. doi: 10.1007/s00262-023-03518-z. Epub 2023 Sep
2023
ASL Cuneo 2
AOU Novara
Santoni M; Porta C; Bellmunt J; Battelli N; Sorgentoni G; Landmesser J; Rizzo A; Mollica V; Zabalza IO; Zgura A; Incorvaia L; Ansari J; Pinto A; Soares A; Nunes F; Maluf F; Morelli F; Mosca A; Zakopoulou R; Bisonni R; Manneh R; Santini D; Inman E; Herchenhorn D; Kanesvaran R; Caitano M; Milella M; Kopecky J; Martignetti A; et alii...
Implementation of Precision Oncology in Clinical Practice: Results of a National Survey for Health Care Professionals. in The oncologist / Oncologist. 2023 Jun 2;28(6):e324-e330. doi: 10.1093/oncolo/oyad020.
2023
ASL Cuneo 2
Aprile G; Cavanna L; Tozzi VD; Silva RR; Ortega C; Giordano M; Pinto C; Daniele B; Grossi F; Barducci MC; Pelizzari G; Fasola G;
Safety of extended interval dosing immune checkpoint inhibitors: a multicenter cohort study. in Journal of the National Cancer Institute / J Natl Cancer Inst. 2023 Jul 6;115(7):796-804. doi: 10.1093/jnci/djad061.
2023
ASL Cuneo 2
AOU Alessandria
Ascierto PA; Aerts JGJV; Grossi F; Rocchi MBL; Cortellini A; Antonuzzo L; Indini A; Santini D; Addeo A; Lo Russo G; Rijavec E; Santoni M; Citarella F; Puglisi F; Manglaviti S; Garutti M; Sergi MC; Tucci M; Giusti R; Acquati M; Filetti M; Cortinovis D; Festino L; Di Giacomo AM; Veccia A; Leporati R; Scagnoli S; Belluomini L; Botticelli A; et alii...
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study. in ESMO open / ESMO Open. 2023 Aug;8(4):101598. doi: 10.1016/j.esmoop.2023.101598. Epub 2023 Jul 17.
2023
AO Cuneo
ASL Cuneo 2
Porta C; Rizzo M; Trerotoli P; Funaioli C; Ricotta R; Santoni M; Ortega C; Giron Berrios JR; Facchini G; Incorvaia L; Zanardi E; Stellato M; Fornarini G; Galli L; Atzori F; Passarelli A; Bersanelli M; Procopio G; Bracarda S; Caffo O; Rudà R; Maiorano BA; Massari F; Internò V;
Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations. in Minerva urology and nephrology / Minerva Urol Nephrol. 2023 Aug;75(4):460-470. doi: 10.23736/S2724-6051.23.05369-7.
2023
AO Cuneo
ASL Cuneo 2
AOU Novara
Grande E; Santoni M; Buti S; Battelli N; Sorgentoni G; Pierantoni F; Monteiro FS; Rebuzzi SE; Roviello G; Soares A; Zabalza IO; Rizzo A; Bisonni R; Morelli F; Incorvaia L; Küronya Z; Mosca A; Bhuva D; Santini D; Vau N; Messina C; Merler S; Landmesser J; Grillone F; Ortega C; Sunela K; Ansari J; Atzori F; Bassanelli M; et alii...
2023
ASL Cuneo 2
Giannatempo P; Bottiglieri A; Guadalupi V; Marandino L; Raggi D; Stellato M; Rametta A; Baciarello G; Sepe P; Claps M; Buti S; Pipitone S; Iacovelli R; Calareso G; Alessi A; Cattaneo L; Verzoni E; Ortega C; Procopio G; Necchi A;
New emerging targets in advanced urothelial carcinoma: Is it the primetime for personalized medicine? in Critical reviews in oncology/hematology / Crit Rev Oncol Hematol. 2022 Jun;174:103682. doi: 10.1016/j.critrevonc.2022.103682. Epub 2022 Apr 11
2022
ASL Asti
ASL Torino 4
ASL Cuneo 1
ASL Cuneo 2
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Buttigliero C; Scagliotti GV; Di Maio M; Ortega C; Di Prima L; Audisio A; Turco F; Ungaro A; Parlagreco E; Di Stefano RF; Audisio M; Tucci M;
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma. in Journal of clinical pathology / J Clin Pathol. 2022 Jan;75(1):39-44. doi: 10.1136/jclinpath-2020-207089. Epub 2020 Nov 3.
2022
ASL Cuneo 2
ASL Cuneo 1
ASL Asti
Antonelli A; Munari E; Pappagallo G; Iacovelli R; Mosca A; Porta C; Martignoni G; Alongi F; Perrucci B; Giganti MO; Donini M; Panni S; Tucci M; Prati V; Ortega C; Caliò A; Procopio G; Verzoni E; Bracarda S; Sabbatini R; Baldessari C; Eccher A; Passalacqua R; Rebuzzi SE; Fornarini G; Vellone VG; Bersanelli M; Buti S; Zivi A; et alii...
Treatment intensification for metastatic prostate cancer: New treatment landscapes in androgen deprivation-based therapy. in Cancer communications (London, England) / Cancer Commun (Lond). 2022 Aug;42(8):683-688. doi: 10.1002/cac2.12340. Epub 2022 Jul 22.
2022
ASL Asti
ASL Cuneo 2
ASL Torino 4
ASL Cuneo 1
AO Ordine Mauriziano
AOU San Luigi di Orbassano
Turco F; Ungaro A; Audisio M; Scagliotti GV; Di Maio M; Delcuratolo MD; Audisio A; Ortega C; Pisano C; Buttigliero C; Di Stefano RF; Tucci M;
Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study. in Journal of personalized medicine / J Pers Med. 2022 Apr 30;12(5):727. doi: 10.3390/jpm12050727.
2022
ASL Asti
AOU Città della Salute di Torino
ASL Cuneo 1
ASL Cuneo 2
Antonelli A; Porta C; Delahunt B; Giannarini G; Signori A; Banna GL; Rescigno P; Obispo MAL; Bortolus R; Perris R; Scaltriti M; Moch H; Fassan M; Dei Tos AP; Colecchia M; Franco R; Zito-Marino F; Aberasturi Plata Y; Galuppini F; Sbaraglia M; Bollito E; Cossarizza A; Massari F; Salvioni R; Rizzo M; Conti G; Lapini A; Colombo P; Patriarca C; et alii...
1337P Implementation of precision oncology in clinical practice: A nationwide survey in Italy in Annals of Oncology
2022
ASL Cuneo 2
Fasola G; Barducci MC; Pelizzari G; Aprile G; Grossi F; Pinto C; Daniele B; Giordano M; Ortega C; Silva RR; Tozzi V; Cavanna L;
Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2021 Sep;155:127-135. doi: 10.1016/j.ejca.2021.06.034. Epub 2021 Aug 6.
2021
AO Cuneo
ASL Asti
ASL Biella
ASL Cuneo 2
AOU Città della Salute di Torino
ASL Città di Torino
AOU Novara
Tucci M; Baier S; Gennari A; Bellissimo AR; Ciccone G; Masini C; Sacco C; Amoroso D; Montagnani F; Comandone A; Ortega C; Buttigliero C; Fea E; Vanella P; Valcamonico F; Zamparini M; Sirotova Z; Chiappino I; Bianchi S; Mosca A; Dalla Volta A; Prati V; Dal Canton O; Berruti A;
Radical metastasectomy followed by sorafenib versus observation in patients withclear cell renal cell carcinoma: extended follow -up of efficacy results from the randomized phase II RESORT trial. in Expert review of clinical pharmacology / Expert Rev Clin Pharmacol. 2021 Feb;14(2):261-268. doi: 10.1080/17512433.2021.1879639. Epub 2021 Jan
2021
ASL Cuneo 2
Procopio G; de Braud FG; Cappelletti V; Guadalupi V; Sepe P; Claps M; Donini M; Ortega C; Atzori F; Morelli F; Bearz A; Miceli R; Chiuri VE; Mosca A; Milella M; Mennitto A; Verzoni E; Cognetti F;
The prognostic nutritional index predicts survival and response to first-line chemotherapy in advanced biliary cancer. in Liver international : official journal of the International Association for the Study of the Liver / Liver Int. 2020 Mar;40(3):704-711. doi: 10.1111/liv.14314. Epub 2019 Dec 11.
2020
ASL Cuneo 2
ASL Biella
AOU Città della Salute di Torino
AO Ordine Mauriziano
Casadei-Gardini A; Aprile G; Roviello G; Scartozzi M; Cascinu S; Silvestris N; Spallanzani A; Santini D; Gelsomino F; Depetris I; Cagnazzo C; Lombardi P; Fenocchio E; Sperti E; Di Maio M; Ortega C; Fornaro L; Aglietta M; Leone F; Cerma K; Salani F; Caputo F; Vivaldi C; Filippi R; Salati M;
Reorganisation of medical oncology departments during the novel coronavirus disease-19 pandemic: a nationwide Italian survey. in European journal of cancer (Oxford, England : 1990) / Eur J Cancer. 2020 Jun;132:17-23. doi: 10.1016/j.ejca.2020.03.024. Epub 2020 Apr 6.
2020
ASL Cuneo 2
ASL Biella
Grossi F; Scanni A; Blasi L; Zamagni C; Pinotti G; Ortega C; Montesarchio V; Giordano M; Fiorentini G; Cavanna L; Clerico M; Fioretto L; Daniele B; Indini A; Aschele C;
2020
ASL Biella
ASL Città di Torino
ASL Asti
AO Cuneo
ASL Cuneo 2
AOU Città della Salute di Torino
Fea E; Buttigliero C; Montagnani F; Comandone A; Gennari A; Tucci M; Chiappino I; Canton OD; Masini C; Sacco† C; Amoroso D; Sirotova Z; Ciccone G; Valcamonico F; Vanella P; Ortega C; Prati V; Bianchi S; Mosca A; Berruti A;
Updated data on patients (pts) with metastatic renal cell carcinoma (mRCC) treated with sorafenib (SOR) vs observation (obs) after radical metastasectomy in the RESORT trial in Annals of Oncology
2020
ASL Cuneo 2
Verzoni E; Claps M; Apollonio G; Guadalupi V; Montone R; Martinetti A; Sepe P; Mennitto A; Passalacqua R; Donini M; Atzori F; Ortega C; Morelli F; Bearz A; Chiuri VE; Mosca A; Milella M; Miceli R; Cognetti F; Procopio G;
Phase II study of avelumab plus intermittent axitinib in previously untreated patients with metastatic renal cell carcinoma (Tide-A study) in Journal of Clinical Oncology
2020
ASL Cuneo 2
AOU San Luigi di Orbassano
Vitale MG; Zucali PA; Milella M; Santoni M; Procopio G; Ortega C; Naglieri E; Massari F; Fornarini G; Di Lorenzo G; Chiuri VE; Calabro F; Fantinel E; Buttigliero C; Bracarda S; Bonomi L; Bersanelli M; Basso U; Atzori F; Iacovelli R;
Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab. in Clinical cancer research : an official journal of the American Association for Cancer Research / Clin Cancer Res. 2019 Jul 1;25(13):3839-3846. doi: 10.1158/1078-0432.CCR-18-3661. Epub 2019 Apr 9.
2019
ASL Cuneo 2
AO Cuneo
Sternberg CN; Caserta C; Cartenì G; Fornarini G; Verusio C; Scoppola A; Crinò L; Frassoldati A; Mini E; Marchetti P; Ortega C; Bidoli P; Ferraù F; Mitterer M; Sabbatini R; Bearz A; Buti S; Basso U; Procopio G; De Giorgi U; Giannarelli D;
Management of kidney cancer patients: 2018 guidelines of the Italian Medical Oncology Association (AIOM). in Tumori / Tumori. 2019 Jul;105(4_suppl):3-12. doi: 10.1177/0300891619853392.
2019
ASL Cuneo 2
Cartenì G; Gori S; Nolè F; Pignata S; Conti G; Guida M; Martignoni G; Pappagallo GL; Romano L; Sepe P; Porta C; Procopio G; Ortega C; Passalacqua R; Montironi R; Martorana G; Masini C; Lapini A; Mandressi A; Di Lorenzo G; Cosmai L; Crocetti E; Bracarda S; Vitale MG;
Real-World Data on Cabozantinib in Previously Treated Patients with Metastatic Renal Cell Carcinoma: Focus on Sequences and Prognostic Factors. in Cancers / Cancers (Basel). 2019 Dec 30;12(1):84. doi: 10.3390/cancers12010084.
2019
ASL Cuneo 2
AO Cuneo
Piva F; Cimadamore A; Montironi R; Battelli N; Rizzo M; Merler S; Sorgentoni G; Conti A; Verzoni E; Scagliarini S; Sepe P; Cheng L; Paolucci V; Graham J; Pierce E; Lopez-Beltran A; Atzori F; Scarpelli M; Ortega C; Incorvaia L; Vau N; Iacovelli R; Mosca A; Gelibter A; Carrozza F; Martignetti A; Morelli F; Caffo O; Zucali P; et alii...
Association of body mass index and systemic inflammation index with survival in patients with renal cell cancer treated with nivolumab in Journal of Clinical Oncology
2019
ASL Cuneo 2
De Giorgi U; Procopio G; Sabbatini R; Caserta C; Mitterer M; Ortega C; Scoppola A; Fornarini G; Ferraú F; Marchetti P; Verusio C; Mini E; Bidoli P; Buti S; Crino L; Basso U; Frassoldati A; Bearz A; Carteni G; Sternberg CN;
Effect of gender on the outcome of patients receiing niolumab for metastatic renal cancer: Results from a large study population in Journal of Clinical Oncology
2019
ASL Cuneo 2
Procopio G; Di Cosimo S; De Giorgi U; Cartenì G; Cortesi E; Caserta C; Sabbatini R; Bearz A; Buti S; Pignata S; Berruti A; Ruggeri E; Bengala C; Livi L; Fagnani D; Bonetti A; Mitterer M; Ortega C; Cognetti F; Di Nicola MA;
The Tumor Entity Denominated "clear cell-papillary renal cell carcinoma" According to the WHO 2016 new Classification, have the Clinical Characters of a Renal Cell Adenoma as does Harbor a Benign Outcome. in Pathology oncology research : POR / Pathol Oncol Res. 2018 Jul;24(3):447-456. doi: 10.1007/s12253-017-0271-x. Epub 2017 Jul 10.
2018
ASL Cuneo 2
Brunelli M; Martignoni G; Ortega C; Lapini A; Cima L; Porta C; Iacovelli R; Tortora G; Ardizzoni A; Guida A; Sanguedolce F; Sabbatini R; D'Amuri A; Giunchi F; Fiorentino M; Caliò A; Hes O; Michal M; Ciccarese C; Massari F;
Cardiovascular safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients: a prospective evaluation. in Future oncology (London, England) / Future Oncol. 2018 Feb;14(5):443-448. doi: 10.2217/fon-2017-0385. Epub 2018 Jan 10.
2018
ASL Cuneo 2
Aglietta M; Ortega C; Marandino L; Nuzzolese I; Torino S; Bonzano A; Galizia D; Gernone A; Aversa C; Ruatta F; Prati V;
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program. in Clinical genitourinary cancer / Clin Genitourin Cancer. 2018 Aug;16(4):e945-e951. doi: 10.1016/j.clgc.2018.03.014. Epub 2018 Apr 19.
2018
ASL Cuneo 2
AOU San Luigi di Orbassano
Facchini G; Cartenì G; Sabbatini R; Del Bene G; Galli L; Caserta C; Multari AG; Bregni M; Massari F; Buti S; De Giorgi U; Zustovich F; Milella M; Calabrò F; Mancini ML; Tortora G; Vernieri C; Santini D; Sorarù M; Ricotta R; Masini C; Tucci M; Fedeli SL; Ortega C; Mecozzi A; Ratta R; Sternberg CN; Verzoni E; Fornarini G; et alii...
A randomized, open label, multicenter phase 2 study, to evaluate the efficacy of sorafenib (So) in patients (pts) with metastatic renal cell carcinoma (mRCC) after a radical resection of the metastases: RESORT trial in Journal of Clinical Oncology
2018
ASL Cuneo 2
Procopio G; Cognetti F; Miceli R; Milella M; Mosca A; Chiuri VE; Bearz A; Morelli F; Ortega C; Atzori F; Donini M; Ratta R; Martinetti A; Montone R; De Braud FG; Cappelletti V; Verzoni E;
Safety and efficacy of abiraterone in elderly patients with metastatic castration-resistant prostate cancer: Multicentric real-life experience in Anticancer Research
2018
ASL Cuneo 2
Sirotova Z; Courthod G; Tartarone A; Caffo O; Maines F; Prati V; Bertuccelli M; Mosca A; Fornarini G; Guglielmini P; Morelli F; Palesandro E; Ortega C; Miraglia S; Perrone V; Numico G; Allegrini G; Aieta M; Schena M;
Safety and efficacy of abiraterone acetate (AA) in patients aged 75 or more with metastatic castration-resistant prostate cancer (mCRPC) in both pre-chemotherapy or post-chemotherapy settings: Real-life experience from thirteen Italian centers in Journal of Clinical Oncology
2018
ASL Cuneo 2
Sirotova Z; Courthod G; Tartarone A; Caffo O; Maines F; Bertuccelli M; Morelli F; Numico G; Guglielmini P; Fornarini G; Prati V; Palesandro E; Ortega C; Mosca A; Miraglia S; Perrone V; Fea E; Allegrini G; Mozzicafreddo A; Schena M;
2017
ASL Cuneo 2
Ricotti A; Ortega C; Brioschi E; Canavese P; Pierini A; Cassissa G; Bono D; Bertetto O; Messori Ioli G;
Safety and efficacy of Cabozantinib for metastatic renal cell carcinoma (mRCC): Real world data from an Italian Expanded Access Program (EAP) in Annals of Oncology
2017
ASL Cuneo 2
Procopio G; Prisciandaro M; Iacovelli R; Mancini M; Fornarini G; Facchini G; Cartení G; Napolitano M; Sternberg CN; Caserta C; Bregni M; Massari F; Buti S; Biasco E; De Giorgi U; Zustovich F; Ratta R; Ortega C; Tortora G; Verzoni E;
Outcome of Patients with Renal Cell Carcinoma and Multiple Glandular Metastases Treated with Targeted Agents in Oncology (Switzerland)
2017
ASL Cuneo 2
Grassi P; Doucet L; Giglione P; Grünwald V; Melichar B; Galli L; De Giorgi U; Sabbatini R; Ortega C; Santoni M; Bamias A; Verzoni E; Derosa L; Studentova H; Porcu L; De Braud F; Porta C; Procopio G;